Fair to say i didn't foresee a backslide of that magnitude, holy smokes. I'd expect the stock to settle around NZ$1.50-$1.75 on this update.
With NZ$78m recurring revenue and a guided cost base of NZ~$81m (FY19 was ~$85M pre bad debt, so ~$81M net of $4m cost savings), the midpoint of this guidance ($10m EBITDA) implies total non-recurring revenue of ~NZ$13m. To put that non-recurring revenue figure in context, the four prior years were:
- FY16: $22.8m
- FY17: $32.4m
- FY18: $40.6m
- FY19: $33.5m
I'm still undecided as to whether this is a true annus horribilis event or something worse. This clearly isn't an ~11% EBITDA margin business (which is what FY20 guidance now is, i.e. ~$10m / ~$90m), but it's clear the embedded growth story is in a shambles at least for the time being.
- Forums
- ASX - By Stock
- Ann: FY20 Outlook Update
GTK
gentrack group limited
Add to My Watchlist
1.22%
!
$11.62

Fair to say i didn't foresee a backslide of that magnitude, holy...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$11.62 |
Change
0.140(1.22%) |
Mkt cap ! $1.251B |
Open | High | Low | Value | Volume |
$11.45 | $11.78 | $11.34 | $1.700M | 146.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4 | $11.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.69 | 968 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4 | 11.350 |
1 | 75 | 11.200 |
2 | 550 | 11.100 |
1 | 90 | 11.010 |
3 | 151 | 11.000 |
Price($) | Vol. | No. |
---|---|---|
11.690 | 968 | 1 |
11.800 | 500 | 1 |
12.000 | 50 | 1 |
12.100 | 69 | 1 |
12.150 | 136 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
GTK (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online